Table 2.

Univariate and multivariable models for “clinical activity”

Independent variable	Univariate analysis		Multivariable analysis*
	OR (95% CI)	P value	OR (95% CI)	P value
Sex	2.706 (0.888–8.24)	0.080
Age (years)	0.976 (0.939–1.015)	0.231
Disease duration (years)	0.979 (0.919–1.043)	0.513
N. of DMTs before OCR	0.100 (0.958–1.642)	0.100
EDSS before infusion A	1.138 (0.855–1.516)	0.374
Patients with relapses in the year before infusion A	0.661 (0.188–2.322)	0.518
Patients with MRI activity in the year before infusion A	1.773 (0.699–4.496)	0.228
Time on OCR therapy (from start to infusion A, months)	0.930 (0.877–0.986)	0.016	0.821 (0.736–0.915)	0.001
EID	2.827 (0.929–8.599)	0.070
CD19 + B-cell depletion rate before infusion A	1.428 (0.550–3.702)	0.464
CD19 + B-cell depletion rate before infusion B	0.914 (0.306–2.735)	0.873
CD19 + B-cell depletion rate before infusion C	0.164 (0.042–0.638)	0.009	0.750 (0.032–0.948)	0.043

OR odds ratio, DMTs disease modifying therapies, EID extended interval dosing, EDSS expanded disability status scale, MRI magnetic resonance imaging, N number, OCR ocrelizumab, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2

^*R² 0.5